• President Trump says he is open to 'great healthcare,' signaling willingness to negotiate but not endorsing a specific deal.
  • The remark comes as ACA silver premiums are set to rise about 13% for 2027 and the administration advances stricter eligibility verification.
  • Trump's January framework to redirect subsidies and lower drug prices remains a proposal, with key details unresolved.

President Trump on Friday said he is open to "great healthcare," a statement that signals a willingness to engage on healthcare policy but stops short of embracing a specific legislative fix. The comment, which echoes similar conciliatory language from his first term, comes as Americans face another year of double-digit premium increases and as his administration moves to tighten eligibility for federal insurance subsidies.

The White House has described Trump's proposed "Great Healthcare Plan" as a framework for Congress to enact. That plan, unveiled in January, calls for redirecting subsidy money to eligible individuals, lowering prescription-drug prices, funding cost-sharing reductions, and requiring clearer insurer disclosures and healthcare pricing. But critical details—including eligibility, payment amounts, and which insurance plans could receive the money—remain unresolved in the published framework.

Meanwhile, affordability pressures are mounting. November reporting puts the average increase in ACA silver-plan premiums for 2027 at approximately 13%, following a substantial increase for 2026. Employer-plan premiums are also rising, with marketplace data showing increases of roughly 8%–10%. Those trends are squeezing households that do not qualify for subsidies, according to health-policy experts.

Separately, the Centers for Medicare & Medicaid Services (CMS) in October proposed requiring verification of income, household size, citizenship, residence, and other coverage before ACA financial assistance begins, starting in 2028. CMS estimates the rule would reduce enrollment by about 332,500 people annually. The proposal is not yet in effect.

The administration argues that greater price transparency, consumer control, and lower drug prices—including through "most-favored-nation" arrangements that link U.S. drug prices to lower prices abroad—would reduce costs. The White House also cites projected savings from funding cost-sharing reductions, a reversal from Trump's first term, when his administration halted those payments. But outside analysts caution that the framework lacks enough detail to assess its impact on coverage for people with pre-existing conditions. KFF has noted that some transparency measures overlap with existing ACA requirements.

For insurers, the central risk is the composition of the insurance pool. Allowing public assistance to purchase coverage outside ACA rules could attract healthier customers away from ACA-compliant plans, leaving a sicker, more expensive pool behind, KFF explains. However, that outcome depends on the legislation; narrower health-savings-account approaches likely would not create the same risk.

The political backdrop is also complex. The expiration of enhanced ACA subsidies and restrictions from the 2025 Republican tax-and-spending law are already reshaping enrollment and affordability, independent of the broader framework. And on November 19, a federal judge blocked administration conditions that would restrict certain HIV-care providers from recognizing transgender patients' gender identities or providing gender-affirming care—a ruling separate from insurance reform but indicative of the legal challenges facing executive healthcare policies.

Trump's remark on Friday drew parallels to October 2017, when he said he was open to a one- or two-year healthcare agreement with Democrats after contacting Senate Democratic leader Chuck Schumer. Schumer responded then that repeal was off the table but that Democrats would consider improvements to the existing system. That episode illustrates why openness to talks is different from agreement on policy.

The White House did not respond to a request for comment on the president's statement. A spokesperson for CMS declined to comment on the proposed verification rule beyond the published notice.